Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 4
2020 6
2021 15
2022 10
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Bachert C, et al. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Lancet. 2019. PMID: 31543428 Clinical Trial.
Safety was assessed in a pooled population of both dupilumab groups in SINUS-52 up to week 24 and the dupilumab group in SINUS-24 and the placebo groups in both studies until week 24. ...Dupilumab significantly improved the coprimary endpoints in both studies …
Safety was assessed in a pooled population of both dupilumab groups in SINUS-52 up to week 24 and the dupilumab group in SINUS …
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, Qiu H, Huang X, Yang Q. Wu Q, et al. Int Arch Allergy Immunol. 2022;183(3):279-288. doi: 10.1159/000519228. Epub 2021 Oct 4. Int Arch Allergy Immunol. 2022. PMID: 34607329
INTRODUCTION: Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). ...Dupilumab had the best efficacy in terms of nasal polyp score (NPS), Sino- …
INTRODUCTION: Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhin …
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J, Bachert C, Amin N, Desrosiers M, Hellings PW, Han JK, Jankowski R, Vodicka J, Gevaert P, Daizadeh N, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Mullol J, et al. J Allergy Clin Immunol Pract. 2022 Apr;10(4):1086-1095.e5. doi: 10.1016/j.jaip.2021.09.037. Epub 2021 Oct 7. J Allergy Clin Immunol Pract. 2022. PMID: 34628065 Free article. Clinical Trial.
BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. ...Dupilumab improved …
BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasa …
Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA. De Prado Gomez PharmD MSc L, et al. Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15. Am J Rhinol Allergy. 2022. PMID: 35837739 Clinical Trial.
Dupilumab inhibits the dual signaling pathways of interleukin (IL)-4 and IL-13, which are key and central drivers of type 2 inflammation in CRSwNP. ...The primary objective is to assess the efficacy of dupilumab compared to omalizumab in reducing the nasal po …
Dupilumab inhibits the dual signaling pathways of interleukin (IL)-4 and IL-13, which are key and central drivers of type 2 inflammat …
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT, Wagenmann M, Bernstein JA, Khan AH, Nash S, Jacob-Nara JA, Siddiqui S, Rowe PJ, Deniz Y. Peters AT, et al. Allergy Asthma Proc. 2023 Jul 1;44(4):265-274. doi: 10.2500/aap.2023.44.230015. Allergy Asthma Proc. 2023. PMID: 37480206 Clinical Trial.
Baseline characteristics were generally similar between patients with and those without AR. Dupilumab significantly improved objective and patient-reported measures of CRSwNP, including loss of smell, and reduced systemic and nasal biomarker levels versus placebo at …
Baseline characteristics were generally similar between patients with and those without AR. Dupilumab significantly improved objectiv …
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.
Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Oykhman P, et al. J Allergy Clin Immunol. 2022 Apr;149(4):1286-1295. doi: 10.1016/j.jaci.2021.09.009. Epub 2021 Sep 17. J Allergy Clin Immunol. 2022. PMID: 34543652 Free article.
BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory condition of the upper airways. ...The risk of rescue nasal polyp surgery likely decreased with dupilumab (risk difference [RD] -16.35% [95% CI -18.13, -13.48]), omalizumab (R …
BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory condition of the upper airways. ...The risk of re …
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C, Inoue T, Takahashi Y, Fujita H, Deniz Y, Rowe P, Ortiz B, Li Y, Mannent LP. Fujieda S, et al. Allergy. 2022 Jan;77(1):186-196. doi: 10.1111/all.14906. Epub 2021 Jun 4. Allergy. 2022. PMID: 33993501 Free PMC article. Clinical Trial.
Dupilumab, on background mometasone furoate nasal spray (MFNS), improved outcomes in the phase III SINUS-52 study (NCT02898454) in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). ...Coprimary endpoints were change from baseline in n …
Dupilumab, on background mometasone furoate nasal spray (MFNS), improved outcomes in the phase III SINUS-52 study (NCT02898454 …
Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps.
Haxel BR, Hummel T, Fruth K, Lorenz K, Gunder N, Nahrath P, Cuevas M. Haxel BR, et al. Rhinology. 2022 Dec 1;60(6):435-443. doi: 10.4193/Rhin22.129. Rhinology. 2022. PMID: 36150163 Clinical Trial.
METHODS: This per protocol analysis included patients with an indication for biological treatment because of uncontrolled CRSwNP, despite long-term nasal steroid treatment, systemic steroid use and/ or endonasal sinus surgery. ...CONCLUSIONS: This real-world study shows th …
METHODS: This per protocol analysis included patients with an indication for biological treatment because of uncontrolled CRSwNP, despite lo …
[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps].
Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, Bachert C. Klimek L, et al. HNO. 2021 Nov;69(11):868-877. doi: 10.1007/s00106-021-01018-z. Epub 2021 Mar 18. HNO. 2021. PMID: 33738558 Free PMC article. Review. German.
On October 24, 2019, the European Commission granted extended approval for dupilumab as the first biological agent for treatment of insufficiently controlled severe CRSwNP. ...RESULTS: Based on the present data, the G-BA decided that there is an indication of a considerabl …
On October 24, 2019, the European Commission granted extended approval for dupilumab as the first biological agent for treatment of i …
Biologics for chronic rhinosinusitis.
Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Chong LY, et al. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. Cochrane Database Syst Rev. 2021. PMID: 33710614 Free PMC article.
Chronic rhinosinusitis is common. It is characterised by inflammation of the nasal and sinus linings, nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. ...Of 1262 adult participants, 1260 had severe chronic rhinosinusitis with nasal …
Chronic rhinosinusitis is common. It is characterised by inflammation of the nasal and sinus linings, nasal blockage, rhinorrh …
33 results

Searches related to "dupilumab nasal"